Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07276373 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 19, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 4 to 5v6
  2. Re-verified, no change to tracked fieldsv5
  3. Study sites: 3 to 4v4
  4. Study sites: 2 to 3v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date changed from estimate of Dec 2025 to Jan 16, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of Dec 2025 to Jan 16, 2026
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Trial Details
NCT Number NCT07276373
Lead Sponsor Corcept Therapeutics
Conditions Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov